ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2185 entries already.
A challenge whose success lies in efficient process management and digital development! The times of digitalisation and Industry 4.0 do not stop at the production of medical cannabis for the pharmaceutical industry. The combination of IT systems and blockchain-based processes allows the value-added chain to be automated and the data generated to be mapped in a tamper-proof manner.
Viennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcyte’s electroporation platform for APN401 development.
After closing the business merging with blank check company Arya Sciences Acquisition Corp, Immatics Inc has been listed on Nasdaq.
A new insulin formulation allows patients with diabetes to more quickly manage their blood sugar levels during mealtimes.
Data from the UK’s RECOVERY trial demonstrate there was no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients.
Under the Coronavirus Global Response Framework, the European Commission is allocating further €4.9bn to assure access to COVID-19 countermeasures for poor countries.
The medical cannabis market has grown significantly in recent years. In Germany, the quantity of imported cannabis products has increased dramatically. In comparison to only 1.2 tons in 2017, German medical cannabis distributors imported about 3.13 metric tons of cannabis flowers for direct medical care of patients in 2018, while around 120 kg have been re-exported. In 2019, this amount doubled to around 6.7 tons.
BioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at €105m.
OneProjects Ltd, an Irish-German cardiac imaging specialist, has closed an €11m Series A financing led by Amsterdam-headquartered life sciences investor LSP.
Illumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs.